EPO and chronic kidney disease: Our study represents the pioneering network meta-analysis (NMA) to evaluate both direct and indirect impacts of various doses of daprodustat, recombinant human erythropoietin (rhEPO), and placebo on anemia in dialysis-dependent chronic kidney disease (CKD) patients.